Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma

被引：107

作者：

Chen, Robert ^{[1
]}

Palmer, Joycelynne M. ^{[2
]}

Thomas, Sandra H. ^{[1
]}

Tsai, Ni-Chun ^{[2
]}

Farol, Len ^{[3
]}

Nademanee, Auayporn ^{[1
]}

Forman, Stephen J. ^{[1
]}

Gopal, Ajay K. ^{[4
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Div Biostat, Duarte, CA 91010 USA

[3] City Hope Kaiser Permanente, Los Angeles, CA USA

[4] Univ Washington, Fred Hutchinson Canc Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA

来源：

BLOOD | 2012年 / 119卷 / 26期

基金：

美国国家卫生研究院;

关键词：

RECEPTOR;

D O I：

10.1182/blood-2012-03-418673

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the efficacy and safety of subsequent reduced-intensity allo-HCT. Seventeen patients had previous autologous transplant; 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from unrelated or mismatched donors. The 1-year overall survival was 100%, progression-free survival was 92.3%, and nonrelapse mortality was 0% (median follow-up, 14 months). The incidence of acute GVHD was 27.8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT. (Blood. 2012;119(26):6379-6381)

引用

页码：6379 / 6381

页数：3

共 16 条

[11]

2-F

[12]

Horning SJ, 2008, INT C MAL LYMPH LUG, piv120

[13] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[14] Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome [J].

Robinson, Stephen P. ;

Sureda, Anna ;

Canals, Carmen ;

Russell, Nigel ;

Caballero, Dolores ;

Bacigalupos, Andrea ;

Iriondo, Arturo ;

Cook, Gordon ;

Pettitt, Andrew ;

Socie, Gerard ;

Bonifazi, Francesca ;

Bosi, Alberto ;

Michallet, Mauricette ;

Liakopoulou, Effie ;

Maertens, Johan ;

Passweg, Jakob ;

Clarke, Fiona ;

Martin, Rodrigo ;

Schmitz, Norbert .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (02) :230-238

[15] Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the lymphoma working party of the European group for blood and marrow transplantation [J].

Sureda, Anna ;

Robinson, Stephen ;

Canals, Carmen ;

Carella, Angela M. ;

Boogaerts, Marc A. ;

Caballero, Dolores ;

Hunter, Ann E. ;

Kanz, Lothar ;

Slavin, Shimon ;

Cornelisson, Jan J. ;

Gramatzki, Martin ;

Niederwieser, Dietger ;

Russell, Nigel H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :455-462

[16] Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation [J].

Wadleigh, M ;

Richardson, PG ;

Zahrieh, D ;

Lee, SJ ;

Cutler, C ;

Ho, V ;

Alyea, EP ;

Antin, JH ;

Stone, RM ;

Soiffer, RJ ;

DeAngelo, DJ .

BLOOD, 2003, 102 (05) :1578-1582

← 1 2 →